01 吉利德科学公司宣布，美国FDA已授予Trodelvy突破性疗法认定，用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前，Trodelvy已在超过50个国家和地区获批，用于治疗经治转移性三阴性乳腺癌 ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...

01 特瑞普利单抗 III 期 EXTENTORCH 研究在 48 个中心共纳入 442 例经组织学或细胞学证实为广泛期小细胞肺癌（ES-SCLC）的患者，将患者以 1:1 比例随机 ...

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...

安全审查委员会 (SRC)已确定REQORSA的推荐二期剂量 (RP2D)为0.12 mg/kg，这是一期试验中测试的最高剂量水平。二期扩展将在10至15个美国站点评估约50名患者的18周无进展生存率。尽管该股票显示出显著的波动性，beta值为-1.38，但分析师保持看涨观点，目标价为7.50美元。

【财华社讯】翰森制药(03692.HK)公布，GSK就GSK5764227(GSK’227，亦称 ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...

这是该产品在中国获批的第五项适应症，也是继鳞状非小细胞肺癌（sqNSCLC)、广泛期小细胞肺癌（ES-SCLC)后，该产品在肺癌领域获批的第三项适应症。

(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...